The concentration of haptoglobin in sera of healthy women and patients with non-malignant and malignant ovarian tumours was measured by two methods, i.e. complex formation with haemoglobin and complex formation with concanavalin A. High correlation (r = 0.74) between both the methods was found in the group of healthy women, but correlation coefficients were much lower in the group of non-malignant and malignant tumours (r = 0.42 and 0.37, respectively). Direct determinations of haptoglobin, and calculation of the ratio of haptoglobin bound to concanavalin A to haptoglobin bound to haemoglobin revealed statistically significant differences among the examined groups. Comparison of two methods of haptoglobin quantitation suggest that processes connected with ovarian disorders may alter the glycosylation of haptoglobin oligosaccharide chains.
Introduction
Haptoglobin is a genetically determined a 2 -^acid glycoprotein, present in most body fluids. The oligosaccharide moiety of haptoglobin consists of N-acetylglucosamine, mannose, galactose, fucose, and sialic acid, forming biand trianntennary N-linked glycans. Haptoglobin is an "acute phase" reactant. Its plasma level is increased in malignancy, trauma, infection, inflammation, tissue damage, but decreased in haemolytic conditions, and since haptoglobin is synthesised in the liver (1) it is also decreased in severe hepatocellular deficiency.
Haptoglobin (Hp) is known to form with haemoglobin (Hb) a stable, practically irreversible complex (Hp-Hb), which in vitro has the activity of a "true" peroxidase. This property is exploited for the quantitative determination of haptoglobin (2) . Formation of the Hp-Hb complex is a function of the polypeptide moiety of haptoglo-bin (1) . On the other hand, the specific arrangement of carbohydrates in haptoglobin enables it to bind plant leetins. The reactivity of the mannose-type core of haptoglobin with concanavalin A, which was utilized in the lectin-ELISA estimation of haptoglobin in body fluids, may change with alterations in haptoglobin glycosylation (3) . Thus, changes in the measured concentrations of haptoglobin under various pathological conditions could be related to quantitative differences in hepatic haptoglobin synthesis, or/and to qualitative differences in the haptoglobin glycans.
Complex metabolic processes occuring in cancer include changes in structure and composition of the oligosaccharide chains of glycoproteins (increases/decreases in the content of specific carbohydrates, changes in antennary structure). These phenomena are very relevant clinically (4, 5) .
In our previous paper haptoglobin determinations (by means of haemoglobin binding) in sera of patients with ovarian cancer were used to monitor the effects of chemotherapy (6) . We also demonstrated some differences in the quantitation of haptoglo in in pathological body fluids, between the "traditional" Hp-Hb method and the method based on Hp-concanavalin A complex formation (7) . The purpose of the present study was to investigate whether these reactivities of haptoglobin, as determined in the sera of patients with ovarian tumours, might be used as an index of disease activity.
Materials and Methods

Samples
Control group (Group I) was established with sera from 37 healthy non-pregnant women (28-57 years old), attending medical followup in the Medical Diagnostic Centre in Wroclaw. Serum samples were chosen for their normal haptoglobin values and on the basis of routine laboratory tests (erythrocyte sedimentation rate, activities of aminotransferases and acid phosphatase, glucose concentration etc.). Non-haemolysed serum samples were stored at -20 °C until analysed.
Pathological sera were collected from 99 women attending the Clinic of Gynaecology of Wroclaw University of Medicine. These preoperative patients were divided into two groups. Group II samples were taken from 56 women (25-61 years old) with non-malignant gynaecologic tumours (cysts, myomas). Sera from 43 patients (31-77 years old), suffering from ovarian carcinomas (FIGO stages II-IV) were assigned to Group III. The staging was performed according to FIGO rules (8) .
The procedure of the assay was as follows: wells of the polystyrene microtitre plate were incubated at 37 °C for 3 h with 0. ). After blocking with 5 g/1 bovine serum albuniih, 100 μΐ of haptoglobin standard solutions (10-100 ng/well) and 100 μΐ of diluted test samples (usual dilutions: 5000 and 10000 times) were added and incubated for l h at 37 °C. After washing 4 times with washing buffer containing 20 g/1 polyethylene glycol 6000 (PEG), 100 μΐ of anti-Hp monoclonal antibody (clone 7.60.66.55) conjugated with peroxidase diluted (2000 times) with washing buffer (see above) was dispensed and the plate was incubated for 30 min at 37 °C. The plate was washed and the enzymatic activity was developed with 0-phenylenediamine. The absorbance was read at 492 nm against a reference wavelength on a Hamilton UV HR 7000 ELISA reader.
Samples were analysed in triplicate after two dilutions to avoid an excess of glycoprotein. Controls were included for each experl· ment. Background absorbances (with buffer instead serum, but with all other reagents) ranged from 0.3 to 0.5, depending on the plate and day of the experiment. Absorbance values for negative control (human serum without haptoglobin confirmed by Hp-Hb-ELISA (7)) were the same as background.
The amount of haptoglobin bound to concanavalin A was calculated from a standard curve prepared for each plate. The useful range of the standard curve was 50-600 μg/l. A standard preparation of haptoglobin containing 0.2% fucose, 2.6% mannose, 2.0% N-acetylglucosamine, was used (9).
Quantification of haptoglobin based on its reactivity with haemoglobin
The Hp-Hb complex displays "true" peroxidase activity. The cleavage of hydrogen peroxide is indicated by guaiacol according to Jones & Mould (2), as follows. Wells of the microtitration plate were cleaned and washed and used in place of small tubes. To the wells were added: -50 μΐ of Hp standard (5-300 mg/1 9 g/1 NaCl) or 5 μΐ of serum sample in 50 μΐ of 9 g/1 NaCl -50 μΐ 0.5 g/1 horse methaemoglobin solution.
The control reagent sample containing all reagents and 50 μΐ of saline instead of Hp was included in each series of estimations. A "blank" was prepared for each serum, containing the reagents and serum sample but without methaemoglobin. The plate was incubated for 10 min in room temperature, followed by addition of 150 μΐ of guaiacol reagent (6.82 g guaiacol, 183 ml of 1 mol/1 acetic acid added to 700 ml distilled water, adjusted to pH 4.0, then made up to 1 litre with distilled water) and 50 μΐ of 0.02 mol/1 hydrogen peroxide solution. After 5 min, absorbance at 492 nm was measured in a Hamilton HR 7 000 reader. Serum haptoglobin concentration was caluclated from a standard curve prepared for each plate.
Quantification of haptoglobin based on its reactivity with concanavalin A The conditions of the assay for glycosylated haptoglobin bound to concanavalin A have been described in 1. c. (3) . The lower detection limit of the assay calculated as 3 SD for the mean of the blank sample was 50 μg/l. The intra-assay (within-day) and inter-assay (between day) coefficients of variation were 4-7% and 6-9%, respectively, as analysed using sera with low, medium and high contents of haptoglobin bound to concanavalin A. The recovery of haptoglobin bound to concanavalin A in the presence of other glycoproteins was higher than 97%.
Statistical calculations
The average, median and standard deviation, lower and upper quartile, distribution of variables, correlation coefficient r and probability level among the examined groups (Wilcoxon test) were calculated.
Results
Haptoglobin concentration was estimated in sera of patients with non-malignant (Group II) and malignant (Group III) ovarian tumours as compared with control healthy women (Group I). The determinations were carried out in parallel, using two methods i. e. complex formation with Hb and complex formation with concanavalin A ( fig. 1 ). Correlation coefficients for both methods were: in the control group r = 0.74, in the group of non-malignant tumours r = 0.42, and in the cancer group r = 0.37. Table 1 summarises the statistical data of the Hp-concanavalin A and Hp-Hb determinations. The ratio of Hpconcanavalin A to Hp-Hb was also calculated. In the control group, the three measured values are rather similar (approximately 1). In the group of non-malignant tumours the mean value for Hp-Hb was twice as high as in the control group, while Hp-concanavalin A was only a little higher. In the group of ovarian cancers Hp-Hb was more than three times and Hprconcanavalin A more than four times higher than in the'control group. In both As can be seen in figure 2 , the majority of Hp-Hb and Hp-concanavalin A determinations in the pathological groups remained outside the limits (more than 70% and about 60%, respectively). Differences in Hp-Hb and Hpconcanavalin A measurements are also apparent in the ratio. Thus, in the group with non-malignant tumours 10% of the ratio values were higher, 30% lower and 60% normal, whereas in the cancer group 30% of the respective results were higher, 40% lower and only 30% "normal".
It is worth pointing out that the ratio in pathological groups was "normal" in some cases when the Hp-Hb was abnormal or was "off-limits" when Hp-Hb was "normal". For instance Hp-Hb and Hp-concanavalin A concentrations in a patient with ovarian cancer were extremely high: 6.7 g/1 and 7.3 g/1, respectively, hence the It is well documented that quantitative changes in the concentrations of acute phase proteins during certain pathophysiological states, particularly in inflammatory conditions and cancer, often accompany specific alterations of the carbohydrate moieties of glycoproteins. Changes in the degree of branching (major microheterogeneity) or/and in terminal glycosylation of glycoproteins (minor microheterogeneity) originate from modifications in the post-translational glycosylation mechanism in the liver or from degradative processes in the circulation (4, 5, 15, 16) .
The introduction of affinity chromatography and crossed affinity electrophoresis of haptoglobin with plant lectins (concanavalin A and wheat germ agglutinin), leading to the appearance of several microheterogeneous forms, was shown to be of value in the differential diagnosis of ovarian cancer and other inflammatory conditions. The carbohydrate moiety of haptoglobin from ascitic fluids of patients with ovarian carcinoma was apparently changed as judged from the reactions with haemoglobin and concanavalin A (17, 18) . Investigations of ovarian cancer haptoglobins using digoxigenin-labelled lectins suggest that normal and ovarian cancer haptoglobins differ in their content of carbohydrate structures containing sialic acid-linked a(2-6) or a(2-3) to galactose and in the type of glycan branching (9). Turner's group (19) (20) (21) (22) has shown that ovarian cancer sera have high levels of an abnormal form of haptoglobin in which fucose occupies three positions (mainly a(l-3)) in carbohydrate chains. The fucose content of haptoglobin was elevated 7-fold in ovarian cancer. The increased fucosylation of haptoglobin was closely related to tumour burden and also correlated with the serum levels of α-3-fiicosyl transferase. Analyses of galactose and N-acetylglucosamine contents of haptoglobin suggest that there are more oligosaccharide branches on the "cancer haptoglobin". The present work shows the amount of haptoglobin that can react with concanavalin A in sera from women with ovarian tumours. We compared these levels with haptoglobin concentrations as measured by the traditional haptoglobin-haemoglobin peroxidase method (2) . Comparisons were expressed as ratio values of Hp-concanavalin A to Hp-Hb. The lectin concanavalin A binds with bi-, but not tri-or tetraantennary N-linked glycans, but the presence of an additional bisecting GlcNAc residue on the Man of the biantennary units inhibits this binding.
Hp-Hb
The degree of reactivity with concanavalin A depends on the number of biantennary structures present on the molecule and could help to reveal major microheterogeneity in glycoproteins.
Measurements of Hp-concanavalin A and Hp-Hb in the present paper provide interesting data on the differential diagnosis of malignant against non-malignant ovarian tumours, as well as non-malignant tumours against other physiological states (see statistically significant differences). In both pathological groups, about 60% of results were "off limits" ( fig. 2 ). Moreover some differences in Hp-concanavalin A concentrations between non-malignant and malignant groups were observed, namely, 31% and 33% of results in non-malignant vs. 9 and 49% in malignant sera were lower and higher than "normal", respectively. In spite of the above mentioned facts, we think that the comparison of Hp-concanavalin A with Hp-Hb estimations (i. e. calculation of the ratio) could give valuable information on the degree of glycosylation of Hp present in the blood of patients. During ovarian disorders, haptoglobin, an acute phase protein, is increased 2-5-fold, as measured by its reaction with haemoglobin. The results of Hp-concanavalin A and HpHb measurements in all the patients with ovarian tumours fall into three subgroups.
First subgroup: no differences in Hp-concanavalin A and Hp-Hb measurements were found (ratio 0.97 ± 0.52), possibly signifying that no differences in the degree of branching of haptoglobin glycans were detected and that the antennary structure of haptoglobin glycans in these patients was similar to that present in healthy women. Sixty percent of the ratio in non-malignant group and 30% in ovarian cancer were "normal".
Second subgroup: the Hp-concanavalin A level was significantly higher than the Hp-Hb level (ratio higher than 1.5); this was observed in 10 and 30% of analysed samples in non-malignant and cancer disease, respectively. These samples probably contained increased amount of haptoglobin glycoforms with biantennary glycans.
Third subgroup: the Hp-concanavalin A level was lower than the Hp-Hb (ratio lower than 0.45). This kind of pattern was noticed in 30% and 40% of data in nonmalignant and cancer disease, respectively. It is predicted that these samples are rich in tri-or higher antennary haptoglobin glycans, or biantennary glycans containing an additional bisecting N-acetylglucosamine.
Mackiewicz & Kushner (15) have postulated that changes in the glycosylation patterns of acute phase proteins in patient sera during acute inflammation differ from those seen in chronic inflammation. During acute inflammation glycoproteins are characterized by higher amounts of biantennary glycans with increased concanavalin A reactivity. In contrast, in chronic inflammation, a relative increase of tetra-and/or triantennary structures with decreased concanavalin A reactivity were found.
It appears that the haptoglobin of some patients with ovarian tumours (second subgroup) had a higher content of biantennary glycans, while in others (third subgroup) there was an increase of tetra-and triantennary structures. In contrast, the high fucose content in haptoglobin from ovarian cancer patients is known to be branchingindependent (19, 21) .
The results reported here are the starting point for two further lines of study, namely oncological-gynaecological diagnostics and the study of the structure and arrangement of carbohydrates of glycoproteins synthesized in the human organism under the influence of malignancy.
Last but not least we would like to point out that estimations of Hp-concanavalin A and Hp-Hb are rapidly and easily performed and not expensive, making them suitable for use in routine laboratory practice.
